NCT07550374: Phase I Clinical Study of NouvNeu001 Injection for the Treatment of Moderate-to-Advanced Parkinson's Disease in Patients Who Have Previously Undergone Deep Brain Stimulation or Deep Brain Nucleus Lesioning Surgery

Sponsor: iRegene Therapeutics Co., Ltd.. Phase: PHASE1. Conditions: Parkinson's Disease (PD)